Article info
PDFSjögren’s syndrome
Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome
- Correspondence to Dr James S Rush, Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research Basel, Basel 4058, Switzerland; james.rush{at}novartis.com
Citation
Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome
Publication history
- Received June 13, 2018
- Revised February 20, 2019
- Accepted February 25, 2019
- First published March 22, 2019.
Online issue publication
May 12, 2021
Article Versions
- Previous version (12 May 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.